Leah Kuntz is a journalist who specializes in writing about psychiatric topics. She has written for Psychiatric Times and her work has also been featured in Drug Topics. Leah's articles cover a range of subjects including novel treatment development for serious mental illness, cognitive impairment in schizophrenia, and new therapies for postpartum depression and schizophrenia.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Leah's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly in mental health research. Her articles often cite data and include expert commentary, indicating a preference for evidence-based information from authoritative sources.
Given Leah's focus on mental health topics and reliance on data-driven insights, she would likely be receptive to pitches that offer access to new research findings or interviews with experts who can provide valuable commentary based on empirical evidence. Additionally, she may be interested in exclusive insights regarding innovative treatments or therapeutic approaches related to mental health disorders.
While Leah does not have a specified geographic focus, her coverage appears global in scope as it encompasses advancements and research across various areas of mental health without being limited to specific regions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The CDC just released new data that highlight issues around adult ADHD prevalence, diagnosis, and treatment.
By: Leah Kuntz
Posters from Psych Congress confirm the durability of long-term treatment with xanomeline/trospium (Cobenfy).
Do you want to be featured in our online series and potentially in print? Check out our November theme!
By: Leah Kuntz, Jeff Futo, Mark R. Munetz
How can we lessen fatal interactions between individuals with mental illness and police? The best possible avenue is partnership and cooperation between mental health clinicians and law enforcement.
A new collaboration to address sleep disturbances associated with cognitive impairment, an unmet need.
By: Leah Kuntz
New positive results demonstrate the efficacy and safety of lumateperone (Caplyta) 42 mg for the prevention of relapse in adult patients with schizophrenia.
By: Leah Kuntz
Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials.
By: Leah Kuntz
The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression.
By: Leah Kuntz
Check out new results of a pharmacokinetics study of AD04, an investigational therapeutic agent for the treatment of alcohol use disorder in patients with heavy drinking.
By: Leah Kuntz, Melissa Fickey
According to new data, NeuroStar Advanced TMS helped nearly 60% of adolescents with major depressive disorder.
(833) 317-6278 
